| | | | | | Product | Package Size | EFP | CP | SB | DC | Composition | Registr. Holder | Category | | |
|---|
| What is an ATC-Code? | ATC-Overview |
|
| L | | IP | CI | | Genotropin 5 mg | ampoule(s) à 5 mg | 154.23 | 184.15 | 10 % | | Injection preparation: Somatropinum Adnr 5.8 mg | Pfizer AG | A / SL / SO | FB | G |
| L | | IP | CI | | Genotropin 5 mg | 5 1 ampoule(s) à 5 mg | 771.17 | 850.80 | 10 % | | Injection preparation: Somatropinum Adnr 5.8 mg | Pfizer AG | A / SL / SO | FB | G |
| L | | IP | CI | | Genotropin 12 mg | ampoule(s) à 12 mg | 373.91 | 423.05 | 10 % | | Injection preparation: Somatropinum Adnr 13.8 mg | Pfizer AG | A / SL / SO | FB | G |
| L | | IP | CI | | Genotropin 5 mg | piece(s) | 154.23 | 184.15 | 10 % | | Injektionspräparat im vorgefüllten Pen GoQuick: Somatropinum Adnr 5.8 mg | Pfizer AG | A / SL / SO | FB | G |
| L | | IP | CI | | Genotropin 5 mg | 5 piece(s) | 771.17 | 850.80 | 10 % | | Injektionspräparat im vorgefüllten Pen GoQuick: Somatropinum Adnr 5.8 mg | Pfizer AG | A / SL / SO | FB | G |
| L | | IP | CI | | Genotropin 12 mg | piece(s) | 373.91 | 423.05 | 10 % | | Injektionspräparat im vorgefüllten Peno GoQuick: Somatropinum Adnr 13.8 mg | Pfizer AG | A / SL / SO | FB | G |
| L | | IP | CI | | Genotropin 12 mg | 5 piece(s) | 1869.52 | 2049.65 | 10 % | | Injektionspräparat im vorgefüllten Peno GoQuick: Somatropinum Adnr 13.8 mg | Pfizer AG | A / SL / SO | FB | G |
| L | | IP | CI | | Omnitrope 5 mg | 5 piece(s) | 701.07 | 778.85 | 10 % | | Injection solution: Somatropinum Adnr 5 mg | Sandoz
Pharmaceuticals AG | A / SL / SG | FB | G |
| L | | IP | CI | | Omnitrope 10 mg | 5 piece(s) | 1402.12 | 1541.30 | 10 % | | Injection solution: Somatropinum Adnr 10 mg | Sandoz
Pharmaceuticals AG | A / SL / SG | FB | G |
| L | | IP | CI | | Omnitrope 15 mg | 5 piece(s) | 2103.20 | 2303.75 | 10 % | | Injection solution: Somatropinum Adnr 15 mg | Sandoz
Pharmaceuticals AG | A / SL / SG | FB | G |
| L | | IP | CI | | Norditropin FlexPro 15 mg | Set(s) | 512.24 | 573.50 | 10 % | | | Novo Nordisk Pharma AG | A / SL | FB | G |
| L | | IP | CI | | Saizen Liquid 6 mg (5.83
mg/ml) | Zylinderampulle(n) | 190.16 | 223.25 | 10 % | | Injection solution: Somatropinum Adnr 6mg / 1.03ml | Merck (Schweiz) AG | A / SL | FB | G |
| L | | IP | CI | | Saizen Liquid 12 mg (8
mg/ml) | Zylinderampulle(n) | 380.33 | 430.05 | 10 % | | Injection solution: Somatropinum Adnr 12mg / 1.5ml | Merck (Schweiz) AG | A / SL | FB | G |
| L | | IP | CI | | Saizen Liquid 20 mg (8
mg/ml) | Zylinderampulle(n) | 633.88 | 705.80 | 10 % | | Injection solution: Somatropinum Adnr 20mg / 2.5ml | Merck (Schweiz) AG | A / SL | FB | G |
| L | | IP | CI | | Norditropin FlexPro 5 mg | Set(s) | 171.06 | 202.45 | 10 % | | Injection preparation: Somatropinum Adnr 5 mg | Novo Nordisk Pharma AG | A / SL | FB | G |
| L | | IP | CI | | Norditropin FlexPro 10 mg | Set(s) | 341.71 | 388.05 | 10 % | | Injection preparation: Somatropinum Adnr 10 mg | Novo Nordisk Pharma AG | A / SL | FB | G |
| L | | IP | CI | | Humatrope 6 mg | Zylinderampulle(n) | 196.76 | 230.40 | 10 % | | Lyophilisate and solvent: Somatropinum Adnr 6 mg | Eli Lilly (Suisse) SA | A / SL | FB | G |
| L | | IP | CI | | Humatrope 12 mg | Zylinderampulle(n) | 393.50 | 444.35 | 10 % | | Lyophilisate and solvent: Somatropinum Adnr 12 mg | Eli Lilly (Suisse) SA | A / SL | FB | G |
| L | | IP | CI | | Humatrope 24 mg | Zylinderampulle(n) | 787.02 | 872.35 | 10 % | | Lyophilisate and solvent: Somatropinum Adnr 24 mg | Eli Lilly (Suisse) SA | A / SL | FB | G |
| | | IP | CI | | Omnitrope 5 mg | | 160.91 | 201.10 | k.A. | | Injection solution: Somatropinum Adnr 5 mg | Sandoz
Pharmaceuticals AG | A | FB | G |
| | | IP | CI | | Omnitrope 5 mg | 10 piece(s) | | | k.A. | | Injection solution: Somatropinum Adnr 5 mg | Sandoz
Pharmaceuticals AG | A | FB | G |
| | | IP | CI | | Omnitrope 10 mg | | | | k.A. | | Injection solution: Somatropinum Adnr 10 mg | Sandoz
Pharmaceuticals AG | A | FB | G |
| | | IP | CI | | Omnitrope 10 mg | 10 piece(s) | | | k.A. | | Injection solution: Somatropinum Adnr 10 mg | Sandoz
Pharmaceuticals AG | A | FB | G |
| | | IP | CI | | Omnitrope 15 mg | piece(s) | | | k.A. | | Injection solution: Somatropinum Adnr 15 mg | Sandoz
Pharmaceuticals AG | A | FB | G |
| | | IP | CI | | Saizen 8 mg click.easy | Set(s) | 379.31 | 451.85 | k.A. | | Injection preparation: Somatropinum Adnr 8.8 mg | Merck (Schweiz) AG | A | FB | G |
| | | IP | CI | | Saizen 8 mg click.easy | 5 Set(s) | 1829.09 | 2067.55 | k.A. | | Injection preparation: Somatropinum Adnr 8.8 mg | Merck (Schweiz) AG | A | FB | G |
|
| L | | IP | CI | | Sogroya 5 mg/ 1.5 ml | 1.5 ml | 252.31 | 290.80 | 10 % | | Injektionslösung im Fertigpen: Somapacitanum 5mg / 1.5ml | Novo Nordisk Pharma AG | A / SL | FB | G |
| L | | IP | CI | | Sogroya 10 mg/ 1.5 ml | 1.5 ml | 504.62 | 565.20 | 10 % | | Injektionslösung im Fertigpen: Somapacitanum 10mg / 1.5ml | Novo Nordisk Pharma AG | A / SL | FB | G |
| L | | IP | CI | | Sogroya 15 mg/ 1.5 ml | 1.5 ml | 719.69 | 799.10 | 10 % | | Injektionslösung im Fertigpen: Somapacitanum 15mg / 1.5ml | Novo Nordisk Pharma AG | A / SL | FB | G |
|
| L | | IP | CI | | Ngenla 24 mg/ 1.2 ml | 1.2 ml | 284.60 | 325.95 | 10 % | | Injektionslösung im Fertigpen: Somatrogonum 24mg / 1.2ml | Pfizer AG | A / SL | FB | G |
| L | | IP | CI | | Ngenla 60 mg/ 1.2 ml | 1.2 ml | 711.50 | 790.20 | 10 % | | Injektionslösung im Fertigpen: Somatrogonum 60mg / 1.2ml | Pfizer AG | A / SL | FB | G |
|
| L | SIP | IP | CI | | Somavert 10 mg | 30 | 1503.98 | 1652.10 | 10 % | | Lyophilisate and solvent: Pegvisomantum 10 mg | Pfizer AG | A / SL | FB | G |
| L | SIP | IP | CI | | Somavert 15 mg | 30 | 2236.94 | 2449.20 | 10 % | | Lyophilisate and solvent: Pegvisomantum 15 mg | Pfizer AG | A / SL | FB | G |
| L | SIP | IP | CI | | Somavert 20 mg | | 99.95 | 125.10 | 10 % | | Lyophilisate and solvent: Pegvisomantum 20 mg | Pfizer AG | A / SL | FB | G |
| L | SIP | IP | CI | | Somavert 20 mg | 30 | 2976.81 | 3253.90 | 10 % | | Lyophilisate and solvent: Pegvisomantum 20 mg | Pfizer AG | A / SL | FB | G |
|
| | | IP | CI | | Minirin 0,1 mg | 30 Tablet(s) | 19.36 | 37.35 | 10 % | | Tablets: Desmopressini Acetas | Ferring AG | B / SL / SO | FB | G |
| | | IP | CI | | Minirin 0,1 mg | 90 Tablet(s) | 63.69 | 85.30 | 10 % | | Tablets: Desmopressini Acetas | Ferring AG | B / SL / SO | FB | G |
| | | IP | CI | | Minirin 0,2 mg | 30 Tablet(s) | 34.50 | 53.70 | 10 % | | Tablets: Desmopressini Acetas | Ferring AG | B / SL / SO | FB | G |
| | | IP | CI | | Minirin 0,2 mg | 90 Tablet(s) | 110.77 | 136.20 | 10 % | | Tablets: Desmopressini Acetas | Ferring AG | B / SL / SO | FB | G |
| | | IP | CI | | Nocutil | 5 ml | 34.21 | 53.60 | 10 % | | Nasal spray: Desmopressini Acetas | Gebro Pharma AG | B / SL / SG | FB | G |
| | | IP | CI | | Nocutil | 3 x 5 ml | 86.98 | 111.00 | 10 % | | Nasal spray: Desmopressini Acetas | Gebro Pharma AG | B / SL / SG | FB | G |
| | | IP | CI | | Nocutil 0,1 mg | 30 Tablet(s) | 17.42 | 35.35 | 10 % | | Tablets: Desmopressini Acetas | Gebro Pharma AG | B / SL / SG | FB | G |
| | | IP | CI | | Nocutil 0,1 mg | 90 Tablet(s) | 57.32 | 78.75 | 10 % | | Tablets: Desmopressini Acetas | Gebro Pharma AG | B / SL / SG | FB | G |
| | | IP | CI | | Nocutil 0.2 mg | 30 Tablet(s) | 31.05 | 50.20 | 10 % | | Tablets: Desmopressini Acetas | Gebro Pharma AG | B / SL / SG | FB | G |
| | | IP | CI | | Nocutil 0.2 mg | 90 Tablet(s) | 99.69 | 124.85 | 10 % | | Tablets: Desmopressini Acetas | Gebro Pharma AG | B / SL / SG | FB | G |
| L | | IP | CI | | Octostim 15 ug | 10 1 ampoule(s) à 1 ml | 257.92 | 296.90 | 10 % | | Infusion solution: Desmopressini Acetas 15 µg/ml | Ferring AG | B / SL | FB | G |
| | | IP | CI | | Minirin Melt 60 µg | 30 Tablet(s) | 19.36 | 37.45 | 10 % | | Sublingual tablets: Desmopressinum 60 µg | Ferring AG | B / SL | FB | G |
| | | IP | CI | | Minirin Melt 60 µg | 100 Tablet(s) | 70.76 | 93.35 | 10 % | | Sublingual tablets: Desmopressinum 60 µg | Ferring AG | B / SL | FB | G |
| | | IP | CI | | Minirin Melt 120 µg | 30 Tablet(s) | 34.50 | 53.95 | 10 % | | Sublingual tablets: Desmopressinum 120 µg | Ferring AG | B / SL | FB | G |
| | | IP | CI | | Minirin Melt 120 µg | 100 Tablet(s) | 123.07 | 150.25 | 10 % | | Sublingual tablets: Desmopressinum 120 µg | Ferring AG | B / SL | FB | G |
| | | IP | | | Minirin | 10 1 ampoule(s) à 4 ug | | | k.A. | | Injection solution: Desmopressini Acetas 4 µg/ml | Ferring AG | B | FB | G |
| | | IP | CI | | Minirin Melt 240 µg | 30 | | | k.A. | | Sublingual tablets: Desmopressinum 240 µg | Ferring AG | B | FB | G |
| | | IP | CI | | Minirin Melt 240 µg | 100 | | | k.A. | | Sublingual tablets: Desmopressinum 240 µg | Ferring AG | B | FB | G |
| | | IP | CI | | Minirin | 6 ml | 38.66 | 60.80 | k.A. | | Nasal spray: Desmopressini Acetas | Ferring AG | B | FB | G |
| | | IP | CI | | Octostim | 2.5 ml | | | k.A. | | Nasal spray: Desmopressini Acetas 1.5 mg/ml | Ferring AG | B | FB | G |
|
| | | IP | | | Syntocinon 5 I.E. | 5 | 3.61 | 13.15 | 10 % | | Konzentrat zur Herstellung einer Injektions- / Infusionslösung: Oxytocinum 5 UI/ml | CD PHARMA (SUISSE) SA | B / SL | FB | G |
| | | IP | CI | | Syntocinon spray nasale | Spray(s) à 5 ml | | | k.A. | | Solution: Oxytocinum 40 UI/ml | CD PHARMA (SUISSE) SA | ● B | FB | G |
|
| | | IP | | | Carbetocin Ferring 100 ug | 10 | | | k.A. | | Injection solution: Carbetocinum 100 µg | Ferring AG | A | FB | G |
| | SIP | IP | | | Pabal | 5 ampoule(s) | | | k.A. | | Injection solution: Carbetocinum 100 µg | Ferring AG | A | FB | G |
| | | IP | | | Carbetocin Aguettant 100
μg/mL | 5 | | | k.A. | | solution injectable en seringue préremplie: Carbetocinum 100 µg | Aguettant Suisse SA | A | FB | G |
|
| | | IP | | | Lutrelef 3,2 mg | Durchstechflasche(n) | 300.71 | 343.45 | k.A. | | Injection preparation: Gonadorelini Acetas 3.2 mg | Ferring AG | B | FB | G |
|
| | | IP | CI | | Stilamin 3 mg | ampoule(s) | | | k.A. | | Lyophilisate: Somatostatinum 3 mg | Hasten
Biopharmaceutic
(Switzerland) AG | A | FB | G |
| | | IP | CI | | Stilamin 3 mg | | | | k.A. | | Lyophilisate: Somatostatinum 3 mg | Hasten
Biopharmaceutic
(Switzerland) AG | A | FB | G |
|
| L | | IP | CI | | Sandostatin 0,05 mg/mL | 5 1 ampoule(s) à 1 ml | 22.19 | 40.40 | 10 % | | Injection solution: Octreotidum | Novartis Pharma
Schweiz AG | A / SL / SO | FB | G |
| L | | IP | CI | | Sandostatin 0,1 mg/mL | 5 1 ampoule(s) à 1 ml | 41.38 | 61.15 | 10 % | | Injection solution: Octreotidum | Novartis Pharma
Schweiz AG | A / SL / SO | FB | G |
| L | | IP | CI | | Sandostatin 0,5 mg/mL | 5 1 ampoule(s) à 1 ml | 227.65 | 262.60 | 10 % | | Injection solution: Octreotidum | Novartis Pharma
Schweiz AG | A / SL / SO | FB | G |
| L | | IP | CI | | Sandostatin LAR 10 mg
Fertigspritzen | 10 mg | 505.79 | 560.55 | 10 % | | Injection preparation: Octreotidum 10 mg | Novartis Pharma
Schweiz AG | A / SL / SO | FB | G |
| L | | IP | CI | | Sandostatin LAR 20 mg
Fertigspritzen | 20 mg | 897.90 | 982.40 | 10 % | | Injection preparation: Octreotidum 20 mg | Novartis Pharma
Schweiz AG | A / SL / SO | FB | G |
| L | | IP | CI | | Sandostatin LAR 30 mg
Fertigspritzen | 30 mg | 1265.46 | 1377.85 | 10 % | | Injection preparation: Octreotidum 30 mg | Novartis Pharma
Schweiz AG | A / SL / SO | FB | G |
| L | | IP | | | Octreotid Labatec 0,05
mg/mL | 5 1 ampoule(s) à 1 ml | 19.99 | 38.15 | 10 % | | Solution pour injection: Octreotidum | Labatec Pharma SA | A / SL / SG | FB | G |
| L | | IP | | | Octreotid Labatec 0,1
mg/mL | 5 1 ampoule(s) à 1 ml | 37.24 | 56.90 | 10 % | | Solution pour injection: Octreotidum | Labatec Pharma SA | A / SL / SG | FB | G |
| L | | IP | | | Octreotid Labatec 0.2
mg/ml | Durchstechflasche(n) à 5 ml | 69.54 | 92.05 | 10 % | | Solution pour injection: Octreotidum 1mg / 5ml | Labatec Pharma SA | A / SL / SG | FB | G |
| L | | IP | | | Octreotid Labatec 0,5
mg/mL | 5 1 ampoule(s) à 1 ml | 204.98 | 239.35 | 10 % | | Solution pour injection: Octreotidum | Labatec Pharma SA | A / SL / SG | FB | G |
| | | IP | | | Octreotid-Mepha LA 10 mg | | | | k.A. | | Lyophilisate and solvent: Octreotidum 10 mg | Mepha Pharma AG | | FB | G |
| | | IP | | | Octreotid-Mepha LA 20 mg | | | | k.A. | | Lyophilisate and solvent: Octreotidum 20 mg | Mepha Pharma AG | | FB | G |
| | | IP | | | Octreotid-Mepha LA 30 mg | | | | k.A. | | Lyophilisate and solvent: Octreotidum 30 mg | Mepha Pharma AG | | FB | G |
| | | IP | | | Octreotid-Teva 0.05 mg/ml | Durchstechflasche(n) | | | k.A. | | Injektionslösung oder Konzentrat zur Herstellung einer Infusionslösung: Octreotidum | Teva Pharma AG | A | FB | G |
| | | IP | | | Octreotid-Teva 0.05 mg/ml | 5 Durchstechflasche(n) | | | k.A. | | Injektionslösung oder Konzentrat zur Herstellung einer Infusionslösung: Octreotidum | Teva Pharma AG | A | FB | G |
| | | IP | | | Octreotid-Teva 0.1 mg/ml | Durchstechflasche(n) | | | k.A. | | Injektionslösung oder Konzentrat zur Herstellung einer Infusionslösung: Octreotidum | Teva Pharma AG | A | FB | G |
| | | IP | | | Octreotid-Teva 0.1 mg/ml | 5 Durchstechflasche(n) | | | k.A. | | Injektionslösung oder Konzentrat zur Herstellung einer Infusionslösung: Octreotidum | Teva Pharma AG | A | FB | G |
| | | IP | | | Octreotid-Teva 0.2 mg/ml | Durchstechflasche(n) | | | k.A. | | Injektionslösung oder Konzentrat zur Herstellung einer Infusionslösung: Octreotidum | Teva Pharma AG | A | FB | G |
| | | IP | | | Octreotid-Teva 0.5 mg/ml | Durchstechflasche(n) | | | k.A. | | Injektionslösung oder Konzentrat zur Herstellung einer Infusionslösung: Octreotidum | Teva Pharma AG | A | FB | G |
| | | IP | | | Octreotid-Teva 0.5 mg/ml | 5 Durchstechflasche(n) | | | k.A. | | Injektionslösung oder Konzentrat zur Herstellung einer Infusionslösung: Octreotidum | Teva Pharma AG | A | FB | G |
|
| L | | IP | CI | | Somatuline Autogel 60 mg | | 725.83 | 805.80 | 10 % | | Depot-Injektionslösung in einer Fertigspritze: Lanreotidum 60mg / 0.5ml | Ipsen Pharma Schweiz
GmbH | A / SL | FB | G |
| L | | IP | CI | | Somatuline Autogel 90 mg | | 1001.92 | 1106.05 | 10 % | | Depot-Injektionslösung in einer Fertigspritze: Lanreotidum 90mg / 0.5ml | Ipsen Pharma Schweiz
GmbH | A / SL | FB | G |
| L | | IP | CI | | Somatuline Autogel 120 mg | | 1290.70 | 1420.15 | 10 % | | Depot-Injektionslösung in einer Fertigspritze: Lanreotidum 120mg / 0.5ml | Ipsen Pharma Schweiz
GmbH | A / SL | FB | G |
| | | | | | Lanreotid Advanz Pharma 60 mg | | | | k.A. | | Depot-Injektionslösung in einer Fertigspritze: Lanreotidum 60mg / 0.5ml | Advanz Pharma
Specialty Medicine
Switzerland GmbH | A | FB | G |
| | | | | | Lanreotid Advanz Pharma 90 mg | | | | k.A. | | Depot-Injektionslösung in einer Fertigspritze: Lanreotidum 90mg / 0.5ml | Advanz Pharma
Specialty Medicine
Switzerland GmbH | A | FB | G |
| | | | | | Lanreotid Advanz Pharma 120 mg | | | | k.A. | | Depot-Injektionslösung in einer Fertigspritze: Lanreotidum 120mg / 0.5ml | Advanz Pharma
Specialty Medicine
Switzerland GmbH | A | FB | G |
|
| L | | IP | CI | | Signifor 0.3 mg/1 ml | 30 ampoule(s) | 2013.84 | 2206.60 | 10 % | | Injection solution: Pasireotidum | Recordati AG | B / SL | FB | G |
| L | | IP | CI | | Signifor 0.6 mg/1 ml | 30 ampoule(s) | 2013.84 | 2206.60 | 10 % | | Injection solution: Pasireotidum | Recordati AG | B / SL | FB | G |
| L | | IP | CI | | Signifor 0.9 mg/1 ml | 30 ampoule(s) | 2013.84 | 2206.60 | 10 % | | Injection solution: Pasireotidum | Recordati AG | B / SL | FB | G |
| L | | IP | CI | PP | Signifor LAR 20 mg | Durchstechflasche(n) à 20 mg | 3011.01 | 3291.05 | 10 % | | Pulver und Lösung zur Herstellung einer Injektionssuspension: Pasireotidum 20 mg | Recordati AG | A / SL | FB | G |
| L | | IP | CI | PP | Signifor LAR 40 mg | Durchstechflasche(n) à 40 mg | 3011.01 | 3291.05 | 10 % | | Pulver und Lösung zur Herstellung einer Injektionssuspension: Pasireotidum 40 mg | Recordati AG | A / SL | FB | G |
| L | | IP | CI | PP | Signifor LAR 60 mg | Durchstechflasche(n) à 60 mg | 3011.01 | 3291.05 | 10 % | | Pulver und Lösung zur Herstellung einer Injektionssuspension: Pasireotidum 60 mg | Recordati AG | A / SL | FB | G |
| | | IP | CI | PP | Signifor LAR 10 mg | 10 mg | | | k.A. | | Pulver und Lösung zur Herstellung einer Injektionssuspension: Pasireotidum 10 mg | Recordati AG | A | FB | G |
| | | IP | CI | PP | Signifor LAR 30 mg | 30 mg | | | k.A. | | Pulver und Lösung zur Herstellung einer Injektionssuspension: Pasireotidum 30 mg | Recordati AG | A | FB | G |
|
| | | IP | CI | | Orgalutran | | | | k.A. | | Injection solution: Ganirelixum | Organon GmbH | A | FB | G |
| | | IP | CI | | Orgalutran | 5 syringe(s) | | | k.A. | | Injection solution: Ganirelixum | Organon GmbH | A | FB | G |
| | | IP | CI | | Ganirelix Labatec 0,25 mg | | | | k.A. | | solution injectable en seringue préremplie: Ganirelixum | Labatec Pharma SA | A | FB | G |
| | | IP | CI | | Ganirelix Labatec 0,25 mg | 5 | | | k.A. | | solution injectable en seringue préremplie: Ganirelixum | Labatec Pharma SA | A | FB | G |
|
| | SIP | IP | CI | | Cetrotide 0,25 mg | Durchstechflasche(n) | | | k.A. | | | Merck (Schweiz) AG | A | FB | G |
| | | | | | Cetrorelix Leman 0,25 mg | | | | k.A. | | poudre pour solution injectable: Cetrorelixum | Leman SKL SA | A | FB | G |
| | | | | | Cetrorelix Leman 0,25 mg | 7 | | | k.A. | | poudre pour solution injectable: Cetrorelixum | Leman SKL SA | A | FB | G |
|
| | | | | | Yselty 100 mg | 28 | | | k.A. | | Coated tablets: Linzagolixum 100 mg | Labatec Pharma SA | B | FB | G |
| | | | | | Yselty 100 mg | 84 | | | k.A. | | Coated tablets: Linzagolixum 100 mg | Labatec Pharma SA | B | FB | G |
| | | | | | Yselty 200 mg | 28 | | | k.A. | | Coated tablets: Linzagolixum 200 mg | Labatec Pharma SA | B | FB | G |
| | | | | | Yselty 200 mg | 84 | | | k.A. | | Coated tablets: Linzagolixum 200 mg | Labatec Pharma SA | B | FB | G |
|
| | | IP | CI | | Ryeqo | 28 | | | k.A. | | Coated tablets: 3 Active Agents | Gedeon Richter
(Schweiz) AG | B | FB | G |
| | | IP | CI | | Ryeqo | 28 | | | k.A. | | Coated tablets: 3 Active Agents | Gedeon Richter
(Schweiz) AG | B | FB | G |
| | | IP | CI | | Ryeqo | 84 | | | k.A. | | Coated tablets: 3 Active Agents | Gedeon Richter
(Schweiz) AG | B | FB | G |
| | | IP | CI | | Ryeqo | 84 | | | k.A. | | Coated tablets: 3 Active Agents | Gedeon Richter
(Schweiz) AG | B | FB | G |
